ClinicalTrials.gg

Program

IVW-1001

A development code. Also written as “IVW-1001 Ophthalmic Eyelid Wipe 0.2%”, “IVW-1001 Ophthalmic Eyelid Wipe 0.4%” and “IVW-1001 Ophthalmic Eyelid Wipe”.

Its studies are mostly in Dry Eye Syndromes, led by IVIEW Therapeutics.

Furthest: phase 2, since May 1, 20243 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
IVIEW Therapeutics30 open or runningphase 2since May 1, 2024May 1, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 1, 2024First study: phase 2 study in Dry Eye SyndromesFirst studyNCT06400459 · 150 enrolled · United States
  2. Aug 18, 20252 phase 2 studies in Dry Eye SyndromesNCT07140380, NCT07161011

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07161011Dry Eye Syndromes · United States2CompletedNov 3, 202515
NCT07140380Dry Eye Syndromes · United States2CompletedOct 8, 202530
NCT06400459Dry Eye Syndromes · United States2CompletedOct 15, 2024150

How it is read

Names in the registry

  • “IVW-1001 Ophthalmic Eyelid Wipe 0.2%”, 2 entries
  • “IVW-1001 Ophthalmic Eyelid Wipe 0.4%”, 1 entry
  • “IVW-1001 Ophthalmic Eyelid Wipe”, 1 entry
  • “IVW-1001 Ophthalmic Eyelid Wipe 0.1%”, 1 entry

Codes read as this program: IVW1001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.